{"id":908073,"date":"2025-11-10T20:32:39","date_gmt":"2025-11-11T01:32:39","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/capsovision-submits-breakthrough-device-designation-application-to-fda-for-pancreatic-cancer-screening-capsule\/"},"modified":"2025-11-10T20:32:39","modified_gmt":"2025-11-11T01:32:39","slug":"capsovision-submits-breakthrough-device-designation-application-to-fda-for-pancreatic-cancer-screening-capsule","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/capsovision-submits-breakthrough-device-designation-application-to-fda-for-pancreatic-cancer-screening-capsule\/","title":{"rendered":"CapsoVision Submits Breakthrough Device Designation Application to FDA for Pancreatic Cancer Screening Capsule"},"content":{"rendered":"

\nNon-invasive capsule endoscopy system aims to enable earlier detection of pancreatic ductal adenocarcinoma – among the most fatal cancers worldwide
\n<\/h2>\n
\n

SARATOGA, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) — CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) on November 6, 2025 requesting Breakthrough Device Designation (BDD) to accelerate development of the Company\u2019s CapsoCam UGI capsule endoscopy system for use in early-stage pancreatic cancer detection.<\/p>\n

This submission represents an important milestone in CapsoVision\u2019s mission to expand its capsule-based diagnostics platform beyond the small bowel and address some of the most challenging diseases in gastroenterology. Pancreatic ductal adenocarcinoma \u2014 the most common form of pancreatic cancer \u2014 is among the deadliest cancers worldwide, with a five-year survival rate of only 8%, largely because it is diagnosed at advanced stages that cannot be treated. Currently, no early screening tools are recommended to identify the disease at a treatable stage in the general population.<\/p>\n

CapsoVision is pursuing the potential use of its CapsoCam UGI endoscopy to identify pancreatic disease at an earlier stage. The device\u2019s unique panoramic imaging capability enables clear visualization of the duodenal papilla, a small bowel landmark that controls release of digestive fluids. Changes in the papilla\u2019s appearance can be associated with pancreatic abnormalities and may serve as an early indicator of disease.<\/p>\n

Unlike traditional endoscopic or imaging procedures, CapsoCam UGI is completely non-invasive. Patients simply swallow a pill-sized camera, eliminating the need for sedation, intubation, or recovery time, while enabling physicians to review detailed images through a secure, cloud-based system.<\/p>\n

The FDA\u2019s Breakthrough Devices Program is designed to expedite the development and review of technologies that may offer more effective diagnosis or treatment for life-threatening conditions where no adequate alternatives exist. If granted, the designation would allow CapsoVision to work closely with the FDA to accelerate development and shape upcoming clinical studies, leading the regulatory review process.<\/p>\n

\n Pancreatic Cancer Screenings<\/strong>\n <\/p>\n

Pancreatic cancer remains one of the most lethal malignancies, with a five-year survival rate of only 10%\u00b9, a figure that has seen little improvement in decades. It is now the third leading cause of cancer-related death in the United States\u00b2, despite accounting for just over 3% of all cancer cases. Approximately 80% of diagnoses occur at advanced stages\u00b3 when the disease is already unresectable or metastatic, leaving limited options for curative treatment. Existing diagnostic methods including CT, MRI, and endoscopic ultrasound are invasive, costly, and lack the sensitivity needed to detect small or early-stage lesions\u2074.<\/p>\n

Early detection can improve survival more than fourteen-fold5<\/sup>, yet no non-invasive screening method for the general population is currently recommended. This underscores an urgent global need for innovative, patient-friendly diagnostic technologies that can visualize pancreatic abnormalities earlier, before symptoms emerge and while curative treatment is still possible.<\/p>\n

\n About CapsoVision<\/strong>\n <\/p>\n

CapsoVision is a commercial-stage medical technology company focused on developing advanced imaging and AI-enabled solutions to transform the detection and diagnosis of gastrointestinal diseases. Its flagship product, CapsoCam Plus\u00ae, is a wire-free, panoramic capsule endoscope that enables high-resolution visualization of the small bowel and supports cloud-based or direct capsule video retrieval. The Company\u2019s next pipeline product, CapsoCam Colon\u2122 with enhanced AI, is designed to enable non-invasive colon imaging and polyp detection. With a proprietary platform targeted to expand across multiple GI indications, including esophageal and pancreatic disorders, CapsoVision is advancing a new era in capsule-based diagnostics. For more information on CapsoVision, please visit www.capsovision.com<\/a>.<\/p>\n

\n Forward-Looking Statements<\/strong>\n <\/p>\n

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In this context, forward-looking statements mean statements related to future events, which may impact our expected future business and financial performance, and often contain words such as \u201cexpected\u201d, \u201canticipates\u201d, \u201cintends\u201d, \u201cplans\u201d, \u201cbelieves\u201d, \u201cpotential\u201d, \u201cwill\u201d, \u201cshould\u201d, \u201ccould\u201d, \u201cwould\u201d or \u201cmay\u201d and other words of similar meaning. Examples of these forward-looking statements include, but are not limited to, statements concerning possible or assumed future results of operations, including the timing and receipt of regulatory approvals, the Company\u2019s plans, strategies and timing for its pipeline development, and the success of the Company\u2019s plans and strategies. These forward-looking statements are based on the Company\u2019s current expectations and inherently involve significant risks and uncertainties, including those beyond the Company\u2019s control. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, market conditions and the failure to receive regulatory clearance. Specifically, the Company\u2019s proposed capsule endoscopy solution may not meet the eligibility requirements for the Breakthrough Device Designation and, even if a Breakthrough Device Designation is received, it may not receive the FDA authorization required to market the proposed capsule endoscopy solution. These and other risks and uncertainties are described more fully in the Company\u2019s filings with the Securities and Exchange Commission (\u201cSEC\u201d), including the \u201cRisk Factors\u201d section of the Company\u2019s prospectus filed on July 3, 2025 with the SEC, as part of the Company\u2019s Registration Statement on Form S-1 (File No. 333-287148), and the Company\u2019s most recent Form 10-Q. Forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to update or revise these statements, except as required by law.<\/p>\n

\n Investor Relations Contact<\/strong>\n <\/p>\n

Leigh Salvo
New Street Investor Relations
Investors@CapsoVision.com<\/u><\/p>\n

\n Media Contact<\/strong>\n <\/p>\n

Leslie Strickler and Paul Spicer
\u00catre Communications
leslies@etrecommunications.com<\/u> | (804) 240-0807
pauls@etrecommunications.com<\/u> | (804) 503-9231<\/p>\n

\n Sources<\/strong>\n <\/p>\n

    \n
  1. SEER Cancer Statistics Review, 2025. National Cancer Institute.<\/em> https:\/\/seer.cancer.gov\/statfacts\/html\/pancreas.html<\/li>\n
  2. Rawla P, Sunkara T, Gaduputi V. Epidemiology of pancreatic cancer: global trends, etiology and risk factors.<\/em>World Journal of Oncology.<\/em> 2019;10(1):10.<\/li>\n
  3. MD Anderson Cancer Center. Pancreatic Cancer Overview.<\/em> Accessed July 2025. https:\/\/www.mdanderson.org\/cancer-types\/pancreatic-cancer.html<\/li>\n
  4. Olakowski M, Bu\u0142dak \u0141. Current status of inherited pancreatic cancer.<\/em>Hereditary Cancer in Clinical Practice.<\/em> 2022;20(1):26.<\/li>\n
  5. SEER Statistics Network Explorer. U.S. Cancer Statistics.<\/em> https:\/\/seer.cancer.gov\/statistics-network\/explorer<\/li>\n<\/ol>\n

    \"\"
    \n
    \n \"\"\n <\/div>\n

    <\/div>\n","protected":false},"excerpt":{"rendered":"

    Non-invasive capsule endoscopy system aims to enable earlier detection of pancreatic ductal adenocarcinoma – among the most fatal cancers worldwide SARATOGA, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) — CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) on November 6, 2025 requesting Breakthrough Device Designation (BDD) to accelerate development of the Company\u2019s CapsoCam UGI capsule endoscopy system for use in early-stage pancreatic cancer detection. This submission represents an important milestone in CapsoVision\u2019s mission to expand its capsule-based diagnostics platform beyond the small bowel and address some of the most challenging diseases in gastroenterology. Pancreatic ductal adenocarcinoma … <\/p>\n

    Continue reading “CapsoVision Submits Breakthrough Device Designation Application to FDA for Pancreatic Cancer Screening Capsule”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-908073","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nCapsoVision Submits Breakthrough Device Designation Application to FDA for Pancreatic Cancer Screening Capsule - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/capsovision-submits-breakthrough-device-designation-application-to-fda-for-pancreatic-cancer-screening-capsule\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CapsoVision Submits Breakthrough Device Designation Application to FDA for Pancreatic Cancer Screening Capsule - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Non-invasive capsule endoscopy system aims to enable earlier detection of pancreatic ductal adenocarcinoma – among the most fatal cancers worldwide SARATOGA, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) — CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) on November 6, 2025 requesting Breakthrough Device Designation (BDD) to accelerate development of the Company\u2019s CapsoCam UGI capsule endoscopy system for use in early-stage pancreatic cancer detection. This submission represents an important milestone in CapsoVision\u2019s mission to expand its capsule-based diagnostics platform beyond the small bowel and address some of the most challenging diseases in gastroenterology. Pancreatic ductal adenocarcinoma … Continue reading "CapsoVision Submits Breakthrough Device Designation Application to FDA for Pancreatic Cancer Screening Capsule"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/capsovision-submits-breakthrough-device-designation-application-to-fda-for-pancreatic-cancer-screening-capsule\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-11T01:32:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3Mjc0OSM3MjU1NjkxIzIyOTkzNzU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capsovision-submits-breakthrough-device-designation-application-to-fda-for-pancreatic-cancer-screening-capsule\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capsovision-submits-breakthrough-device-designation-application-to-fda-for-pancreatic-cancer-screening-capsule\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"CapsoVision Submits Breakthrough Device Designation Application to FDA for Pancreatic Cancer Screening Capsule\",\"datePublished\":\"2025-11-11T01:32:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capsovision-submits-breakthrough-device-designation-application-to-fda-for-pancreatic-cancer-screening-capsule\\\/\"},\"wordCount\":1011,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capsovision-submits-breakthrough-device-designation-application-to-fda-for-pancreatic-cancer-screening-capsule\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU3Mjc0OSM3MjU1NjkxIzIyOTkzNzU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capsovision-submits-breakthrough-device-designation-application-to-fda-for-pancreatic-cancer-screening-capsule\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capsovision-submits-breakthrough-device-designation-application-to-fda-for-pancreatic-cancer-screening-capsule\\\/\",\"name\":\"CapsoVision Submits Breakthrough Device Designation Application to FDA for Pancreatic Cancer Screening Capsule - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capsovision-submits-breakthrough-device-designation-application-to-fda-for-pancreatic-cancer-screening-capsule\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capsovision-submits-breakthrough-device-designation-application-to-fda-for-pancreatic-cancer-screening-capsule\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU3Mjc0OSM3MjU1NjkxIzIyOTkzNzU=\",\"datePublished\":\"2025-11-11T01:32:39+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capsovision-submits-breakthrough-device-designation-application-to-fda-for-pancreatic-cancer-screening-capsule\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capsovision-submits-breakthrough-device-designation-application-to-fda-for-pancreatic-cancer-screening-capsule\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capsovision-submits-breakthrough-device-designation-application-to-fda-for-pancreatic-cancer-screening-capsule\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU3Mjc0OSM3MjU1NjkxIzIyOTkzNzU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU3Mjc0OSM3MjU1NjkxIzIyOTkzNzU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capsovision-submits-breakthrough-device-designation-application-to-fda-for-pancreatic-cancer-screening-capsule\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CapsoVision Submits Breakthrough Device Designation Application to FDA for Pancreatic Cancer Screening Capsule\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CapsoVision Submits Breakthrough Device Designation Application to FDA for Pancreatic Cancer Screening Capsule - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/capsovision-submits-breakthrough-device-designation-application-to-fda-for-pancreatic-cancer-screening-capsule\/","og_locale":"en_US","og_type":"article","og_title":"CapsoVision Submits Breakthrough Device Designation Application to FDA for Pancreatic Cancer Screening Capsule - Market Newsdesk","og_description":"Non-invasive capsule endoscopy system aims to enable earlier detection of pancreatic ductal adenocarcinoma – among the most fatal cancers worldwide SARATOGA, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) — CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) on November 6, 2025 requesting Breakthrough Device Designation (BDD) to accelerate development of the Company\u2019s CapsoCam UGI capsule endoscopy system for use in early-stage pancreatic cancer detection. This submission represents an important milestone in CapsoVision\u2019s mission to expand its capsule-based diagnostics platform beyond the small bowel and address some of the most challenging diseases in gastroenterology. Pancreatic ductal adenocarcinoma … Continue reading \"CapsoVision Submits Breakthrough Device Designation Application to FDA for Pancreatic Cancer Screening Capsule\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/capsovision-submits-breakthrough-device-designation-application-to-fda-for-pancreatic-cancer-screening-capsule\/","og_site_name":"Market Newsdesk","article_published_time":"2025-11-11T01:32:39+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3Mjc0OSM3MjU1NjkxIzIyOTkzNzU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capsovision-submits-breakthrough-device-designation-application-to-fda-for-pancreatic-cancer-screening-capsule\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capsovision-submits-breakthrough-device-designation-application-to-fda-for-pancreatic-cancer-screening-capsule\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"CapsoVision Submits Breakthrough Device Designation Application to FDA for Pancreatic Cancer Screening Capsule","datePublished":"2025-11-11T01:32:39+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capsovision-submits-breakthrough-device-designation-application-to-fda-for-pancreatic-cancer-screening-capsule\/"},"wordCount":1011,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capsovision-submits-breakthrough-device-designation-application-to-fda-for-pancreatic-cancer-screening-capsule\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3Mjc0OSM3MjU1NjkxIzIyOTkzNzU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capsovision-submits-breakthrough-device-designation-application-to-fda-for-pancreatic-cancer-screening-capsule\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/capsovision-submits-breakthrough-device-designation-application-to-fda-for-pancreatic-cancer-screening-capsule\/","name":"CapsoVision Submits Breakthrough Device Designation Application to FDA for Pancreatic Cancer Screening Capsule - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capsovision-submits-breakthrough-device-designation-application-to-fda-for-pancreatic-cancer-screening-capsule\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capsovision-submits-breakthrough-device-designation-application-to-fda-for-pancreatic-cancer-screening-capsule\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3Mjc0OSM3MjU1NjkxIzIyOTkzNzU=","datePublished":"2025-11-11T01:32:39+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capsovision-submits-breakthrough-device-designation-application-to-fda-for-pancreatic-cancer-screening-capsule\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/capsovision-submits-breakthrough-device-designation-application-to-fda-for-pancreatic-cancer-screening-capsule\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capsovision-submits-breakthrough-device-designation-application-to-fda-for-pancreatic-cancer-screening-capsule\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3Mjc0OSM3MjU1NjkxIzIyOTkzNzU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3Mjc0OSM3MjU1NjkxIzIyOTkzNzU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capsovision-submits-breakthrough-device-designation-application-to-fda-for-pancreatic-cancer-screening-capsule\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"CapsoVision Submits Breakthrough Device Designation Application to FDA for Pancreatic Cancer Screening Capsule"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/908073","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=908073"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/908073\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=908073"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=908073"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=908073"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}